- Home
- SOLV vs RPRX Comparison
SOLV vs RPRX Comparison
Compare SOLV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- RPRX
- Stock Information
- Founded
- SOLV 2023
- RPRX 1996
- Country
- SOLV United States
- RPRX United States
- Employees
- SOLV N/A
- RPRX N/A
- Industry
- SOLV
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOLV
- RPRX Health Care
- Exchange
- SOLV NYSE
- RPRX Nasdaq
- Market Cap
- SOLV 12.7B
- RPRX 13.9B
- IPO Year
- SOLV N/A
- RPRX 2020
- Fundamental
- Price
- SOLV $75.55
- RPRX $36.03
- Analyst Decision
- SOLV Hold
- RPRX Strong Buy
- Analyst Count
- SOLV 10
- RPRX 3
- Target Price
- SOLV $80.29
- RPRX $47.33
- AVG Volume (30 Days)
- SOLV 786.6K
- RPRX 4.3M
- Earning Date
- SOLV 08-07-2025
- RPRX 08-07-2025
- Dividend Yield
- SOLV N/A
- RPRX 2.44%
- EPS Growth
- SOLV N/A
- RPRX 37.60
- EPS
- SOLV 2.18
- RPRX 2.45
- Revenue
- SOLV $8,308,000,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- SOLV $4.11
- RPRX $29.35
- Revenue Next Year
- SOLV $0.14
- RPRX $7.58
- P/E Ratio
- SOLV $34.81
- RPRX $14.72
- Revenue Growth
- SOLV 1.29
- RPRX 1.13
- 52 Week Low
- SOLV $47.16
- RPRX $24.05
- 52 Week High
- SOLV $85.92
- RPRX $36.32
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- RPRX 64.81
- Support Level
- SOLV N/A
- RPRX $35.01
- Resistance Level
- SOLV N/A
- RPRX $36.14
- Average True Range (ATR)
- SOLV 0.00
- RPRX 0.70
- MACD
- SOLV 0.00
- RPRX 0.10
- Stochastic Oscillator
- SOLV 0.00
- RPRX 90.07
About SOLV SOLVENTUM CORP
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.